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Abstract
Background: The retinopathy is an uncommon complication in individuals with sickle cell trait except for the cases
of sickle cell trait associated with systemic arterial hypertension, diabetes mellitus, syphilis, tuberculosis and sarcoidosis.
Case Presentation: A retinopathy in a 16 year-old child with no history of consanguinity in the parents revealed a
sickle S trait associated to heterozygous alpha thalassemia. His mother has Sickle cell anaemia (Hb SS) and his father is
a carrier of heterozygous alpha-thalassemia status that it was unknown before.
Conclusion: This case report describes a proliferative retinopathy in a 16 year-old patient with co-inheritance of
heterozygous alpha + −thalassemia and sickle trait.
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Background
Sickle cell anaemia (SCA) is associated with life-threatening
systemic manifestations results from homozygous inherit-
ance of the haemoglobin (Hb) -S gene from both parents’
results in a homozygote (Hb SS). Also, SCA is due to
compound heterozygosity for HbS and other haemoglobin
variants like HbC, HbE, and HbD, or the many different
genotypes of HbS-β thalassemia. People with SCA have
abnormal haemoglobin which can distort red blood cells
into a sickle shape. They break down more rapidly than
normal red blood cells which can lead to deep anaemia
with all his clinical manifestations [1]. The carrier individ-
uals of sickle cell disease known as sickle cell trait (SCT)
have one gene mutation resulting in the Hb AS genotype.
although this is very rare SCT may have symptoms in-
cluding splenic infarction at high altitude, with extreme
exercise, or hypoxemia, isothenuria with loss of max-
imal renal concentrating ability, haematuria secondary
to renal papillary necrosis, fatal exertional heat illness
with exercise, sudden idiopathic death with exercise,
glaucoma or recurrent hyphema following a first episode
of hyphema, bacteruria or pyelonephritis associated with
pregnancy, Renal medullary carcinoma in young people
and early onset of end stage renal disease from autosomal
dominant polycystic kidney [2]. Both heterozygous (−α/αα)
and homozygous (−α/−α) α + thalassemia are associated
with moderate reductions in both Mean Corpuscular
Volume and Hb [3]. In SCA, homozygous α + thalassaemia
inhibits polymerisation of HbS reducing sickling and the
clinical manifestations of the disease [4]. In patients with
sickle cell trait many cases of retinopathy has been re-
ported [5, 6]. This paper describes the clinical, and the la-
boratory characteristics of a 16 year-old-patient with SCT
associated to heterozygous α + thalassemia.
Case Presentation
A 16-year-old Caucasian patient with no known past
medical history presented with 2 years of blurry vision
in the right eye. He had no other ocular, medical, or surgi-
cal history. He rarely sought medical care and was on no
medications. His mother has Sickle cell anaemia (Hb SS)
(Fig. 1). In December 2013, he consulted an ophthalmolo-
gist for a history of sudden onset of amaurosis (Transient
monocular visual loss) in the right eye associated with
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headaches and dizziness. Dilated fundus examination
found unilateral papilledema in the left eye without loss
of visual acuity. In the interpretation of Humphrey visual
field testing, it has been reported that the right visual field
showed some scotomas. The color vision examination was
normal. Fundus fluorescein angiography (FFA) of the right
eye revealed temporal capillary non-perfusion correspond-
ing to retinal ischemia with no neovascularization (Fig. 2).
FFA of the left eye showed venous tortuosity with no vis-
ible ischemic areas (Fig. 3). The retinopathy in the right
eye was treated successively with scattered argon laser
photocoagulation. There was no diagnosis of intracranial
tumor, the magnetic resonance imaging and the brain
computed tomography were normal.
The retinopathy and the fact that his mother has sickle
cell anaemia motivated a screening test to identify variant
and abnormal haemoglobins (electrophoresis, liquid high
performance chromatography and polymerase chain
reactions). A haemoglobin electrophoresis and genotyping
revealed an heterozygous sickle-cell disease (A/S) associ-
ated with an heterozygous alpha-thalassemia (αα/-α), and
the levels in percentage of the haemoglobin S (HbS), HbF,
HbA and HbA2 was respectively 61.7, 0.8, 33.6 and 3.9%
(Table 1). Patient’s haematological parameters showed
normal haemoglobin level, hypochromia and microcytosis
of the Blood red cells (RBC) (Table 1).
The other family members were studied after obtaining
informed written consent. The screening was performed
on family members because the patient has a sickle cell
trait associated to an heterozygous alpha thalassemia and
his mother has a sickle cell anaemia (Hb SS). The haem-
atological parameters were normal for the patient’s father
and sister even she has a sickle cell trait. Patient’s family
genetic testing revealed the father’s alpha-thalassemia
status which was unknown before (Table 1).
Discussion and Conclusions
A retinopathy in a 16 year-old child with no history of
consanguinity in the parents revealed a sickle S trait as-
sociated to heterozygous alpha thalassemia. His mother
is a carrier of the sickle cell disease and his father is a
Fig. 1 Family sickle cell pedigree chart
Fig. 2 Fluorescein angiography of the patient’s right eye
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Fig. 3 Fluorescein angiography of the patient’s left eye
Table 1 The family biological parameters
Paramètres Patient Sister (A/S) Father(αα/-α) Mother (S/S) Reference values
Hemoglobin (g/dl) 12.8 13.4 14.5 7.1 13–16
MCV (fl) 73.1 86.1 79.4 100.6 78–98
MCHC (pg) 22.91 27.4 24.1 32.7 25–35
Hématocrit (%) 40.2 42 47.7 21.9 37–49
RBC106/μl 5.58 4.88 6.01 2.18 4.5–6.5
Ferritin (ng/ml) 14.5 27.9 28.8 553.2 11–336
Haptoglobin (g/l) 0.91 1.63 1.37 <0.072
Total Bilirubin (mg/l) 5 8 4 23 3–12
Direct Bilirubine (mg/l) <1 1.1 0.3 3.6 1–5
LDH (UI/l) 139 133 127 383 98–192
CRP (mg/l) <1 2.5 <1 4.7 1–7.5
Hemoglobin A (%) 61.7 56 97.2 — 96–98
Hemoglobin S (%) 33.6 40.2 84.3 0
Hemoglobin A2 (%) 3.9 3.2 2.8 3 2–3
Hemoglobin F (%) 0.8 0.6 12.7 <2
Abbreviations: MCV mean corpuscular volume, MCHC mean corpuscular haemoglobin concentration, RBC red blood cell count, LDH lactate dehydrogenase
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carrier of heterozygous alpha-thalassemia status that it was
unknown before. Sickle cell trait has no effect on haemo-
globin concentrations [7], and heterozygous (−α/αα) α +
thalassemia is associated with moderate reductions in both
Mean Corpuscular Volume and haemoglobin concentra-
tion [3]. The retinopathy is an uncommon complication in
individuals with sickle cell trait except for the cases of
sickle cell trait associated with systemic arterial hyperten-
sion, diabetes mellitus, syphilis, tuberculosis and sarcoid-
osis [8–10]. But occurring more frequently in patients with
the most clinically significant haemoglobinopathies: the
SC, the S-thalassemia and the SS and after 20 year-old
[9, 10]. The retinopathy is due to the vaso-occlusive
processes. That is due to the red blood cells deformation
or sickling, the result of polymerization of deoxyHbS and
also high concentrations of unpolymerized oxidized HbS,
modulated by cellular levels of HbF (foetal Hb), erythro-
cyte cation and water content, pH, temperature, and
mechanical stresses that result in membrane damage and
eventual failure. Sickling cells are red blood cells with ab-
normal shape and lower deformability which can cause
them to undergo haemolysis (haemolytic anaemia) [1].
The haemolytic anaemia and the vaso-occlusive processes
lead to retinal hypoxia, ischemia, infarction and neovascu-
larization [9, 11]. This is due to their or be removed by
macrophages in the spleen.
Homozygous alpha-thalassemia (α-/α-) inhibits in vivo
sickling in SCD (homozygous sickle-cell disease). Indeed,
Higgs et al. found that patients with SCD and homozygous
alpha-thalassemia (α-/α-) had significantly higher red-cell
counts and levels of haemoglobin and haemoglobin A2, as
well as significantly lower haemoglobin F, mean corpuscular
haemoglobin, mean corpuscular haemoglobin concentration,
mean corpuscular volume, reticulocyte counts, irreversibly-
sickled-cell counts, and serum total bilirubin levels, than
those with SCA and normal alpha-globin-gene complement.
Heterozygotes (α–/αα) had intermediate values between
those of the patients with homozygous alpha-thalassemia
(α-/α-) and normal alpha genes associated to SCD [12].
Fox et al. studied the influence of homozygous a +
thalassaemia on the retinal complications in patients
with homozygous sickle cell (SS) disease. homozygous
a + thalassaemia reduces the extent of peripheral retinal
vessel closure but has no apparent effect on the fre-
quency of proliferative sickle retinopathy [13].
This case report describes a proliferative retinopathy
in a 16 year-old patient with co-inheritance of heterozy-
gous alpha + −thalassemia and sickle trait. Perhaps this
co-inheritance may reduce the extent of peripheral retinal
vessel closure. More studies with a big number of patients
are needed for the confirmation of this observation.
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